ENDOCRINOLOGY MKSAP 19 TEST
QUESTIONS AND ANSWERS
In suspected Type I DM, what antibodies should be checked? - ANSWER
GAD65 and IA-2
What is the USPSTF recommendation for screening for TIIDM? - ANSWER
Any individual > 35 YO who are overweight or obese
What are the ADA recommendations for screening for TIIDM? - ANSWER
Any patient with a BMI of > 25 w/ one additional risk factor: first degree
relative with TIIDM, high risk race/ethnicity
h/o of gestational diabetes, hx of CVD, physical inactivity, HTN, HDL < 35,
PCOS
A random glucose of > ____ mg/dL w/ a hyperglycemic symptoms is diagnostic
for diabetes and does not warrant repeat measurement - ANSWER 200
A1c will be falsely low in patients with? - ANSWER hemolytic anemia,
patients on erythropoietin, or patients w/ kidney injury
If A1c is not at goal after initiating metformin, what is the preferred next
therapy? - ANSWER SGLT-2: (canagliflozin, dapagliflozin, and
empagliflozin; - flozin) or a GLP-1: (semaglutide, exenatide, dulaglutide,
liraglutide; - tide)
QUESTIONS AND ANSWERS
In suspected Type I DM, what antibodies should be checked? - ANSWER
GAD65 and IA-2
What is the USPSTF recommendation for screening for TIIDM? - ANSWER
Any individual > 35 YO who are overweight or obese
What are the ADA recommendations for screening for TIIDM? - ANSWER
Any patient with a BMI of > 25 w/ one additional risk factor: first degree
relative with TIIDM, high risk race/ethnicity
h/o of gestational diabetes, hx of CVD, physical inactivity, HTN, HDL < 35,
PCOS
A random glucose of > ____ mg/dL w/ a hyperglycemic symptoms is diagnostic
for diabetes and does not warrant repeat measurement - ANSWER 200
A1c will be falsely low in patients with? - ANSWER hemolytic anemia,
patients on erythropoietin, or patients w/ kidney injury
If A1c is not at goal after initiating metformin, what is the preferred next
therapy? - ANSWER SGLT-2: (canagliflozin, dapagliflozin, and
empagliflozin; - flozin) or a GLP-1: (semaglutide, exenatide, dulaglutide,
liraglutide; - tide)
